The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Phase 1 study of MEDI4736, an anti-PD-L1 antibody, in combination with dabrafenib and trametinib or trametinib alone in patients with unresectable or metastatic melanoma.
Michael S. Gordon
Research Funding - MedImmune
Jose Lutzky
Research Funding - MedImmune
Donald P. Lawrence
Research Funding - MedImmune
Keith W. Orford
Employment or Leadership Position - GlaxoSmithKline
Stock Ownership - GlaxoSmithKline
Andy Blake-Haskins
Employment or Leadership Position - MedImmune
Stock Ownership - AstraZeneca
Alessandra Di Pietro
Employment or Leadership Position - MedImmune
Paul B. Robbins
Employment or Leadership Position - MedImmune
Stock Ownership - AstraZeneca
Mohammed M. Dar
Employment or Leadership Position - MedImmune
Stock Ownership - AstraZeneca
Antoni Ribas
Consultant or Advisory Role - Amgen; Genentech; GlaxoSmithKline; Merck
Stock Ownership - Kite Pharma